Introduction
Patients with SSc may have an increased risk of malignancy compared with the general population [1] . A wide array of cancers has been reported in scleroderma, although lung and breast cancers are thought to be the most common [2] .
Papillary thyroid cancer (PTC) presents most commonly between 30-50 years of age, with a preponderance female/male=3:1. The radiation exposure is a risk factor of PTC [3] .
The prevalence of PTC is higher where iodine intake is excessive, or in case of iodine prophylaxis [4] .
A longitudinal follow-up study has shown a high incidence of new cases of hypothyroidism and thyroid dysfunction in female sclerodermic patients, suggesting that the ones who are at high risk (a borderline high [even if in the normal range] thyroid stimulating hormone (TSH) value, anti-thyroperoxidase antibody (AbTPO) positivity, and a hypoechoic and small thyroid) should have periodic thyroid function follow-up [5] .
A few studies have reported sporadic cases of PTC in patients with SSc [6, 7] .
The present (cases/controls) study prospectively investigated prevalence and features of thyroid cancer (TC) in a large series of unselected patients with SSc in comparison with two matched sample from the general population with different iodine intake.
Methods

Subjects
SSc patients. Three hundred twenty-seven SSc patients consecutively referred to the Rheumatology Units of the University of Pisa and Modena (from 1995 to 2009) were recruited into the study. SSc was classified according to the American College of Rheumatology 1980 preliminary criteria [8] . Standardized criteria were followed for the evaluation of clinico-serological features, main visceral organ involvement and disease activity [9] . In SSc patients disease duration ranged from 7 to 112 months; skin sclerosis was observed in all patients (diffuse 52% or limited 48%); visceral involvement included: peripheral vascular system, 94%; gastrointestinal system, 51%; lung, 64%; joint/tendons, 21%; heart, 35%; kidney, 9%. The prevalence of autoantibodies, evaluated according to standard methodologies [9] , was: antinuclear 91% (with nucleolar pattern 24%), anticentromere 37%, anti-topoisomerase I (anti-Scl-70) 41%.
Controls.
Since iodine intake differs within Tuscany, and reliable data on local iodine intake based on urinary iodine excretion are available, two different control groups were used.
1)
Controls from an iodine deficient area. Among 3124 subjects randomly extracted from the general registry of North-West Tuscany and systematically screened for thyroid disorders, 2 individuals of same gender and similar age (± 5 years), for each SSc patient, were randomly selected and used as a population-based, gender-and age-matched control group ( Table 1) .
The majority (87%) of these control subjects had resided in an iodine-deficient area for 20 years or more, which was considered a criterion of historical iodine deficiency.
2) Controls from an iodine sufficient area. Another control group was obtained choosing 2 individuals of same gender and similar age (± 5 years), for each SSc patient, who were randomly extracted from the background population of an area of iodine sufficiency (central Tuscany) who had been screened for thyroid disorders. Among these control subjects 19% had resided in an iodine-deficient area for 20 years or more ( Table 1) .
Control subjects with previous radiotherapy were excluded.
All patients and controls gave informed consent to the study, which was approved by the Institutional Ethics Committee.
All patients and controls underwent a complete clinical evaluation ( Table 1 ) and were prospectively evaluated by TSH, free thyroxine (FT4), free triiodothyronine (FT3), anti-thyroglobulin antibody (AbTg), AbTPO determination, and physical examination, thyroid ultrasonography, fine-needle aspiration (FNA) (if necessary).
Ultrasonography of the neck and FNA.
Neck ultrasonography and FNA were performed as previously reported [3] . FNA was performed in palpable nodules; nodules that were not palpable were examined by FNA only when clinical findings or the echographic pattern [10, 11] suggested the opportunity of excluding malignancy (larger than 8 mm, solid hypoechoic appearance, and/or irregular or blurred margins, and/or microcalcifications) [12] .
Laboratory evaluation.
Serum levels of TSH (DiaSorin, USA; reference range 0.3-3.6 mIU/L), FT3 and FT4 (AMERLEX-MAB FT3/FT4 Kit; Amersham, Little Chalfont, UK), AbTPO and AbTg (ICN Pharmaceuticals, USA; positivity was set at > 100 kIU/L) were evaluated.
Statistical analysis.
Data are expressed as mean ± SD. For continuous variables, group differences were tested by analysis of variance; when this was significant at the P ≤ 0.05 level, between-group comparisons were carried out by the Bonferroni-Dunn test. Group differences were tested for categorical variables, by Fisher's Exact test (two-tailed). Furthermore, Odds Ratio was used when at least 1 case of thyroid disorder was observed in controls. A P value < 0.05 was considered significant. We used StatView software, Version 5.0, SAS Institute Inc., SAS Campus Drive, Cary NC 27513, USA, for statistical analysis.
Results
The samples had similar distributions by gender, age (by selection criteria) and smoking habits ( Table 1) . A positive family history of thyroid disease was significantly more frequent in controls from the iodine-deficient area and in SSc patients than in controls from the iodinesufficient area.
In SSc patients, serum TSH levels, AbTg and AbTPO titers were significantly higher, while FT3 and FT4 were significantly lower in comparison to the other groups ( Table 1) .
Hypothyroidism (defined as a TSH level > 4 mIU/L, in the presence of normal or low values of FT3 and/or FT4) was significantly more common in SSc patients than in the other groups.
The prevalence of subclinical and clinical hyperthyroidism (defined as a TSH level < 0.3 mIU/L, in the presence of normal or high values of FT3 and/or FT4) was not significantly higher in SSc patients ( Table 1) . Non-thyroidal illness syndrome (defined as low serum FT3, normal to low FT4, high reverse T3 [ranging from 1.08 -2.46 nmol/L], and normal TSH) was observed in 3% of SSc patients.
The prevalence of thyroid nodules was higher in control subjects from the iodine-deficient area and in SSc patients than in the controls from the iodine-sufficient area ( Table 1) Following standard criteria [13] , the cytological samples were subdivided into classes: class 1, macrophages and colloid with no or rare follicular cells; class 2, benign nodule; class 3, indeterminate follicular lesion; class 4, suspect or frankly malignant. The distributions of cytological results in SSc, iodine-deficient and iodine-sufficient groups were: class 1 (7%, 8%, 8%, respectively); class 2 (82%, 85%, 86%, respectively); class 3 (4%, 7%, 8%, respectively). No significant differences in the distribution of class 1, 2 and 3 results among the three groups were observed (χ 2 , P = 0.9).
Four class 4 (7%), suspect or frankly malignant cytological results were observed in SSc patients. This class of results was only observed in the SSc group. Thyroidectomy was performed in all patients and controls with class 3 cytology; upon histological examination, a PTC was found in two SSc patients and one subject from both control groups. In the 4 SSc patients with class 4 cytology, post-thyroidectomy histological examination revealed PTC.
To sum up, six PTCs were detected in the SSc series, while only one case was observed in both controls ( Table 2 ). The presence of PTC was not associated with any specific SSc treatment, or duration of the disease.
Discussion
This study first shows that PTC is observed with higher prevalence in SSc patients, with respect to age-and gender-matched iodine-deficient controls, and iodine-sufficient controls.
To eliminate bias in the observed prevalence of TC due to differences in iodine uptake, control groups from both high and low iodine intake regions were used [4] . Nonetheless, the results show a significantly higher prevalence of PTC in SSc patients than in both controls.
The low prevalence of PTC in the control groups is in agreement with the low prevalence of TC (1/1411 subjects screened) recently reported from a population-based study in Southern Italy [10] . However, we cannot completely rule out that surveillance bias may be a possible explanation for finding more cancers in the cases than in controls undergoing routine screening.
The mechanisms connecting SSc and malignancies are unknown. The occurrence of different cancer types with SSc or SSc-like disorders suggests different underlying mechanisms, including altered immune response, common genetic and environmental links, diseasedependent factors, tumor-derived biologic substances and therapies [2] . The process of sclerosis itself may favour cancer in certain sites, such as lung and breast [2] .
In our patients autoimmune thyroid involvement and hypothyroidism were more frequently observed in patients with SSc than in the comparison groups, in agreement with results from other studies [15, 16] . An association between TC and chronic thyroiditis has been observed in many studies [17, 18] .
In our study, features of thyroid autoimmunity were observed in all SSc patients with PTC, in comparison to 40% of SSc patients without TC, reinforcing the hypothesis that thyroid autoimmunity may be a predisposing condition for PTC. In our SSc patients, TSH was higher in the SSc group than in controls, and it is known that nodules are statistically more often malignant in patients with higher TSH [19] . Even if TSH levels in non-nodule-SSc, in benignnodule-SSc and in PTC-SSc were not significantly different, we cannot exclude that a high TSH could be associated with PTC in SSc.
Another hypothesis proposed to explain the increase of cancers in SSc patients is the exposure to medications [2] . However, the presence of PTC was not associated with any specific treatment of SSc in our series. Furthermore, no specific treatment of SSc is known to be associated with TC.
If the BRAF-MEK-ERK pathway activation plays a common role in PTC and SSc remains to be investigated; however, we have found the V600E BRAF mutation was observed in 1 among 3 patients evaluated, in line with the frequency observed in PTC patients without SSc [20] .
In conclusion, this study first shows an increased risk of PTC in SSc patients, and an association with thyroid autoimmunity. As such, we recommend that careful thyroid evaluation (by ultrasonography, FT4, TSH, AbTPO measurements) should be carried out during the follow-up of these patients.
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